Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
Lancaster University, the Natural History Museum, London and Fera we are creating an analytical pipeline that integrates high-throughput DNA sequencing with automated image analysis of invertebrates
-
facilitate an internal People Services delivery structure to ensure alignment and readiness to deliver high-impact change. The role will act as a central coordination point across People Services and be
-
to ensure alignment with both University-wide and School-specific priorities. You’ll also manage a small, dynamic team, delivering a consistent and effective approach to student recruitment marketing
-
of major transformation programmes, helping colleagues understand, engage with, and embrace new ways of working that align with our Vision and Strategy. What we’re looking for You’ll be a confident
-
measurable improvements in institutional performance, stakeholder experience, and alignment with long-term academic and operational goals. In order to be successful, you should have proven experience
-
key role in shaping Faculty and University strategy, driving transformation, and strengthening alignment between Faculty and University-wide services. The Faculties Faculty of Medical Sciences (FMS) is
-
AI and data skills programmes aligned to organisational needs and emerging sector trends and strengthen links with Newcastle University by promoting experimental learning and enabling research impact
-
, and adapt content for digital and print channels, ensuring it is audience-focused, accessible, and aligned with brand and compliance standards. Coordinate the production of marketing materials and
-
and RSS Workforce Development Business Plan and Strategy, promoting a culture of organisational learning. In alignment with Newcastle University's blended working policy, this position allows
-
acquisition and preprocessing. RELMED consists of two randomized clinical trials to be run in sequence. The first trial will start 2025 to 2026. This will be followed by a second trial to be run from mid 2027